Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Verseon

DB:7VC1
Snowflake Description

Overvalued with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7VC1
DB
£12M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
7VC1 Share Price and Events
7 Day Returns
0%
DB:7VC1
-1%
DE Biotechs
1.1%
DE Market
1 Year Returns
-
DB:7VC1
4.8%
DE Biotechs
8.1%
DE Market
7VC1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Verseon (7VC1) 0% 0% 0.7% - - -
DE Biotechs -1% -4.5% -9.5% 4.8% 67.2% 5.5%
DE Market 1.1% 4.3% 5.9% 8.1% 10.8% 21.7%
1 Year Return vs Industry and Market
  • No trading data on 7VC1.
  • No trading data on 7VC1.
Price Volatility
7VC1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Verseon undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Verseon. This is due to cash flow or dividend data being unavailable. The share price is €0.433.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Verseon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Verseon's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7VC1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.16
AIM:VERS Share Price ** AIM (2019-08-01) in GBP £0.07
AIM:VERS Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.289 $0.09
Europe Biotechs Industry PE Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 32.21x
Germany Market PE Ratio Median Figure of 406 Publicly-Listed Companies 19.16x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Verseon.

DB:7VC1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:VERS Share Price ÷ EPS (both in USD)

= 0.09 ÷ -0.16

-0.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Verseon is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Verseon is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Verseon's expected growth come at a high price?
Raw Data
DB:7VC1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
10.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.17x
Germany Market PEG Ratio Median Figure of 262 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Verseon, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Verseon's assets?
Raw Data
DB:7VC1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.13
AIM:VERS Share Price * AIM (2019-08-01) in GBP £0.07
AIM:VERS Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.289 $0.09
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3x
Germany Market PB Ratio Median Figure of 578 Publicly-Listed Companies 1.77x
DB:7VC1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:VERS Share Price ÷ Book Value per Share (both in USD)

= 0.09 ÷ 0.13

0.74x

* Primary Listing of Verseon.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Verseon is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Verseon's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Verseon has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Verseon expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Verseon expected to grow at an attractive rate?
  • Verseon's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Verseon's earnings growth is positive but not above the Germany market average.
  • Unable to compare Verseon's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7VC1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7VC1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 10.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 41.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 33.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7VC1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7VC1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 58 -4 1
2022-12-31 34 -14 1
2021-12-31 0 -40 -41 1
2020-12-31 60 28 26 1
2019-12-31 0 -28 -29 1
2019-10-29
DB:7VC1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 -18 -24
2019-03-31 -18 -23
2018-12-31 -18 -22
2018-09-30 -18 -22
2018-06-30 -18 -22
2018-03-31 -19 -21
2017-12-31 -19 -20
2017-09-30 -19 -20
2017-06-30 -18 -19
2017-03-31 -17 -19
2016-12-31 -16 -19
2016-09-30 -15 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Verseon's earnings are expected to grow by 10.3% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Verseon is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7VC1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Verseon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7VC1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.02 -0.02 -0.02 1.00
2022-12-31 -0.09 -0.09 -0.09 1.00
2021-12-31 -0.26 -0.26 -0.26 1.00
2020-12-31 0.16 0.16 0.16 1.00
2019-12-31 -0.19 -0.19 -0.19 1.00
2019-10-29
DB:7VC1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.16
2019-03-31 -0.15
2018-12-31 -0.14
2018-09-30 -0.14
2018-06-30 -0.14
2018-03-31 -0.14
2017-12-31 -0.13
2017-09-30 -0.13
2017-06-30 -0.13
2017-03-31 -0.13
2016-12-31 -0.13
2016-09-30 -0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Verseon will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Verseon's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Verseon has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Verseon performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Verseon's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Verseon does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Verseon's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Verseon's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Verseon's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Verseon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7VC1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -24.00 10.98 13.13
2019-03-31 -22.78 9.59 13.38
2018-12-31 -21.56 8.20 13.63
2018-09-30 -21.63 7.86 14.13
2018-06-30 -21.70 7.52 14.62
2018-03-31 -21.04 7.38 14.41
2017-12-31 -20.39 7.23 14.20
2017-09-30 -19.70 7.01 13.16
2017-06-30 -19.02 6.78 12.12
2017-03-31 -19.25 6.71 11.41
2016-12-31 -19.48 6.63 10.71
2016-09-30 -17.96 6.36 9.33
2016-06-30 -16.44 6.10 7.95
2016-03-31 -12.06 5.81 6.10
2015-12-31 -7.69 5.51 4.24
2015-09-30 -9.25 7.09 4.81
2015-06-30 -6.56 5.70 3.98
2015-03-31 -7.32 5.05 3.73
2014-12-31 -8.09 4.40 3.47
2014-09-30 0.00 -3.85 1.47 1.96
2013-12-31 0.16 -2.80 0.94 1.31
2012-12-31 -2.74 0.72 1.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Verseon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Verseon has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Verseon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Verseon's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Verseon has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Verseon's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Verseon's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Verseon's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Verseon's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Verseon's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Verseon Company Filings, last reported 3 months ago.

DB:7VC1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 23.98 27.25 2.26
2019-03-31 23.98 27.25 2.26
2018-12-31 25.20 26.38 3.64
2018-09-30 25.20 26.38 3.64
2018-06-30 35.56 26.17 19.24
2018-03-31 35.56 26.17 19.24
2017-12-31 45.22 2.57 11.62
2017-09-30 45.22 2.57 11.62
2017-06-30 56.12 0.00 30.81
2017-03-31 56.12 0.00 30.81
2016-12-31 64.95 0.00 46.87
2016-09-30 64.95 0.00 46.87
2016-06-30 74.88 0.00 62.61
2016-03-31 74.88 0.00 62.61
2015-12-31 83.85 0.22 74.68
2015-09-30 83.85 0.22 74.68
2015-06-30 90.65 1.35 93.57
2015-03-31 90.65 1.35 93.57
2014-12-31 -4.34 2.04 0.02
2014-09-30 -3.86 2.08 0.21
2013-12-31 -9.58 5.03 0.01
2012-12-31 -8.70 4.84 0.02
  • Verseon's level of debt (113.6%) compared to net worth is high (greater than 40%).
  • Verseon had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Verseon has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Verseon has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Verseon's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Verseon has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Verseon's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Verseon dividends.
If you bought €2,000 of Verseon shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Verseon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Verseon's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7VC1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.7%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7VC1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-10-29

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Verseon has not reported any payouts.
  • Unable to verify if Verseon's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Verseon's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Verseon has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Verseon's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Verseon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Verseon has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Verseon's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adityo Prakash
COMPENSATION $300,000
TENURE AS CEO 17.8 years
CEO Bio

Mr. Adityo Prakash serves as Chief Executive Officer at Verseon Corporation since 2002. Mr. Prakash is the Co-founder of Pulsent Corporation. Mr. Prakash co-founded Pulsent with the vision of catalyzing the convergence of Television and the Internet through solutions that serve the fundamental needs of the convergence marketplace. He held various management and technology positions at Cellnet Data Systems and Oracle Corporation prior to which he was involved in research work in mathematical physics. Mr. Prakash combines a comprehensive background in business, technology, research and development with a strategic understanding of the needs of emerging digital video streaming markets. He serves as Executive Director of Verseon Corporation. He received his B.S. in Mathematics and Physics from Caltech.

CEO Compensation
  • Adityo's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Adityo's remuneration is higher than average for companies of similar size in Germany.
Management Team

Adityo Prakash

TITLE
CEO & Executive Director
COMPENSATION
$300K
TENURE
17.8 yrs

Eniko Fodor

TITLE
Founder
COMPENSATION
$300K
AGE
51

David Kita

TITLE
Founder and Vice President of R&D
Board of Directors Tenure

Average tenure and age of the Verseon board of directors in years:

0.8
Average Tenure
71
Average Age
  • The average tenure for the Verseon board of directors is less than 3 years, this suggests a new board.
Board of Directors

Thomas Hecht

TITLE
Non-Executive Chairman
AGE
72

Adityo Prakash

TITLE
CEO & Executive Director
COMPENSATION
$300K

Eniko Fodor

TITLE
Founder
COMPENSATION
$300K
AGE
51

Steve Chu

TITLE
Scientific and Clinical Advisors Board
AGE
71

Sangtae Kim

TITLE
Non-Executive Director
TENURE
0.9 yrs

Ajay Kakkar

TITLE
Scientific and Clinical Advisors Board
TENURE
0.8 yrs

John Deanfield

TITLE
Scientific and Clinical Advisors Board
TENURE
0.8 yrs

Keith Fox

TITLE
Scientific and Clinical Advisors Board
TENURE
0.8 yrs

C. Gibson

TITLE
Scientific and Clinical Advisors Board
TENURE
0.8 yrs

Gregory Lip

TITLE
Scientific and Clinical Advisors Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Verseon's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Verseon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors, as well as metabolic disorders. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.

Details
Name: Verseon Corporation
7VC1
Exchange: DB
Founded: 2002
£13,890,636
159,694,988
Website: http://www.verseon.com
Address: Verseon Corporation
47071 Bayside Parkwa,
Fremont,
California, 94538,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM VERS Common Shares London Stock Exchange AIM Market GB GBP 07. May 2015
OTCPK VERS Common Shares Pink Sheets LLC US USD 07. May 2015
LSE VSN Common Shares London Stock Exchange GB USD 07. May 2015
DB 7VC1 COM USD0.001 (REG S CAT 3) Deutsche Boerse AG DE EUR 02. Apr 2019
AIM VER2 COM USD0.001 (REG S CAT 3) London Stock Exchange AIM Market GB GBP 02. Apr 2019
Number of employees
Current staff
Staff numbers
0
Verseon employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/10/29 22:25
End of day share price update: 2019/08/01 00:00
Last estimates confirmation: 2019/07/25
Last earnings filing: 2019/09/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.